Alterations in B-cell differentiation pathway and JAK–STAT pathway tended to be more frequent in cured DLBCL (86.7% and 66.7%) than recurred DLBCL (45.5% and 18.2%). The gene discussed is SOAT1; the disease is diffuse large B-cell lymphoma.